6TH INTERNATIONAL MULTIDISCIPLINARY COURSE ON IRON DEFICIENCY (IMCID)

PharmaNutra to play a key role, presenting new studies on iron deficiency

Pisa, 11 April 2018 – This week, PharmaNutra will be taking part in two important international events, both to be held in Lisbon (Portugal) from 12 to 14 April.

On 13 and 14 April, the Portuguese capital will be hosting the sixth edition of the International Multidisciplinary Course on Iron Deficiency (IMCID), organised once again this year by PharmaNutra in collaboration with Zambon, the company’s commercial partner for Spain and Portugal. The international course will be presenting specialists in the sector from all over the world, focusing on an in-depth look into iron deficiency anaemia. During the two-day event, doctors and researchers will be presenting the data obtained from clinical studies developed with Sucrosomial® technology, as well as a series of posters illustrating the scientific results achieved by products in the SiderAL® line.

It has now been demonstrated at international level that the efficacy of Sucrosomial® technology is revolutionising iron deficiency treatment. The patent developed by Alesco, a company belonging to PharmaNutra S.p.A. Group, is the result of a technology unrivalled worldwide, which can make a significant contribution to improving the quality of life of people suffering from iron deficiency. This has also been confirmed by the recent study entitled «Sucrosomial Iron Supplementation in Anemic Patients with Celiac Disease Not Tolerating Oral Ferrous Sulfate», promoted by the centre for the prevention and diagnosis of coeliac disease of the IRCCS Ca’ Granda Foundation of Milan and published in Nutrients, in which it is shown clearly that for people with coeliac disease (who are frequently anaemic due to their gluten-free diet and damage to their intestinal mucosae), taking Sucrosomiale® Iron is more effective and better tolerated than traditional iron.

This is not the only date on PharmaNutra’s Lisbon agenda. In the two days before the course, the University of Lisbon will be hosting the 19th edition of the “NATA Symposium”, the European event dedicated to transfusion medicine. NATA’s scientific programme focuses on the developments of scientific research regarding issues such as anaemia, optimising patient blood management and thrombosis. PharmaNutra will be present at the NATA Symposium with a space coordinated by the Scientific Department for the presentation of the scientific studies conducted on Sucrosomial® technology and the products in the SiderAL® line. Thanks to the high level of absorption and tolerability, the result of a unique, patented mechanism, Sucrosomial® Iron supplements are now recognised as the most effective and innovative in the sector, both in the world of medicine and science and among consumers.
For Information:

**PharmaNutra S.p.A.**

Founded in Pisa in 2003 and headed by the Chairman Andrea Lacorte and the Vice Chairman Roberto Lacorte, the aim of PharmaNutra is to develop innovative nutraceutical products and medical devices. An outstanding name in the Italian pharmaceutical sector, the company is present in 38 countries worldwide, and directly employs some 50 people (nine of them researchers). The company has its own network of around 150 pharmaceutical representatives, and collaborates, amongst others, with the Universities of Pisa, Milan, Brescia, Modena, Verona, Barcelona and Brisbane. PharmaNutra is currently European market leader in iron-based dietary supplements, with the patented product SiderAL, which in Italy holds a value market share of 50% of the OTC oral iron market. 2017 saw the market debut of Cetilar, a formulation fully patented and produced by PharmaNutra, which confirms the excellent quality of the scientific research carried out by the Tuscan company. [http://www.PharmaNutra.it](http://www.PharmaNutra.it)